S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.17 (+-0.01%)
AAPL   115.89 (-0.84%)
MSFT   214.76 (-0.02%)
FB   278.42 (-0.11%)
GOOGL   1,609.98 (+1.51%)
AMZN   3,178.00 (-0.22%)
TSLA   426.46 (+0.90%)
NVDA   533.80 (-1.33%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.75 (+5.87%)
MU   53.95 (+1.20%)
AMD   81.05 (+2.34%)
T   28.24 (+5.69%)
F   8.22 (+4.71%)
ACB   4.85 (+0.00%)
GILD   62.95 (+4.55%)
NFLX   485.23 (-0.78%)
BA   169.01 (+3.14%)
NIO   27.41 (-1.62%)
BAC   24.90 (+3.53%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.17 (+-0.01%)
AAPL   115.89 (-0.84%)
MSFT   214.76 (-0.02%)
FB   278.42 (-0.11%)
GOOGL   1,609.98 (+1.51%)
AMZN   3,178.00 (-0.22%)
TSLA   426.46 (+0.90%)
NVDA   533.80 (-1.33%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.75 (+5.87%)
MU   53.95 (+1.20%)
AMD   81.05 (+2.34%)
T   28.24 (+5.69%)
F   8.22 (+4.71%)
ACB   4.85 (+0.00%)
GILD   62.95 (+4.55%)
NFLX   485.23 (-0.78%)
BA   169.01 (+3.14%)
NIO   27.41 (-1.62%)
BAC   24.90 (+3.53%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.17 (+-0.01%)
AAPL   115.89 (-0.84%)
MSFT   214.76 (-0.02%)
FB   278.42 (-0.11%)
GOOGL   1,609.98 (+1.51%)
AMZN   3,178.00 (-0.22%)
TSLA   426.46 (+0.90%)
NVDA   533.80 (-1.33%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.75 (+5.87%)
MU   53.95 (+1.20%)
AMD   81.05 (+2.34%)
T   28.24 (+5.69%)
F   8.22 (+4.71%)
ACB   4.85 (+0.00%)
GILD   62.95 (+4.55%)
NFLX   485.23 (-0.78%)
BA   169.01 (+3.14%)
NIO   27.41 (-1.62%)
BAC   24.90 (+3.53%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.17 (+-0.01%)
AAPL   115.89 (-0.84%)
MSFT   214.76 (-0.02%)
FB   278.42 (-0.11%)
GOOGL   1,609.98 (+1.51%)
AMZN   3,178.00 (-0.22%)
TSLA   426.46 (+0.90%)
NVDA   533.80 (-1.33%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.75 (+5.87%)
MU   53.95 (+1.20%)
AMD   81.05 (+2.34%)
T   28.24 (+5.69%)
F   8.22 (+4.71%)
ACB   4.85 (+0.00%)
GILD   62.95 (+4.55%)
NFLX   485.23 (-0.78%)
BA   169.01 (+3.14%)
NIO   27.41 (-1.62%)
BAC   24.90 (+3.53%)
Log in
OTCMKTS:IPCIF

Intellipharmaceutics International News Headlines

$0.19
-0.01 (-7.27 %)
(As of 10/21/2020 12:48 PM ET)
Add
Compare
Today's Range
$0.19
Now: $0.19
$0.21
50-Day Range
$0.09
MA: $0.13
$0.22
52-Week Range
$0.06
Now: $0.19
$0.95
Volume27,205 shs
Average Volume105,774 shs
Market Capitalization$4.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76

Headlines

Intellipharmaceutics International (OTCMKTS IPCIF) News Headlines Today

Source:
DateHeadline
Intellipharmaceutics International (OTCMKTS:IPCIF) Stock Price Crosses Above 200 Day Moving Average of $0.14Intellipharmaceutics International (OTCMKTS:IPCIF) Stock Price Crosses Above 200 Day Moving Average of $0.14
americanbankingnews.com - October 22 at 3:05 AM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2020 ResultsIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2020 Results
finanznachrichten.de - October 15 at 6:43 PM
IntelliPharmaCeutics Intl Inc (OTCMKTS:IPCIF) Short Interest Up 340.0% in SeptemberIntelliPharmaCeutics Intl Inc (OTCMKTS:IPCIF) Short Interest Up 340.0% in September
americanbankingnews.com - October 14 at 10:50 PM
Short Interest in IntelliPharmaCeutics Intl Inc (OTCMKTS:IPCIF) Drops By 64.3%Short Interest in IntelliPharmaCeutics Intl Inc (OTCMKTS:IPCIF) Drops By 64.3%
americanbankingnews.com - September 27 at 7:56 AM
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of Intellipharmaceutics Common StockKahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of Intellipharmaceutics Common Stock
finance.yahoo.com - August 17 at 2:25 PM
"Intellipharmaceutics Announces That The Company And Purdue Pharma L.P. et al Have Entered Into A Stipulated Dismissal Agreement To Terminate Purdue Patent Litigation, Subject To Court Approval""Intellipharmaceutics Announces That The Company And Purdue Pharma L.P. et al Have Entered Into A Stipulated Dismissal Agreement To Terminate Purdue Patent Litigation, Subject To Court Approval"
finance.yahoo.com - July 2 at 11:22 AM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2020 ResultsIntellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2020 Results
www.finanznachrichten.de - May 29 at 6:29 PM
Intellipharmaceutics Announces Receipt of Cannabis Drug License from Health CanadaIntellipharmaceutics Announces Receipt of Cannabis Drug License from Health Canada
www.bloomberg.com - April 27 at 8:38 AM
Intellipharmaceutics Announces FDA Approval for Generic Pristiq(R)Intellipharmaceutics Announces FDA Approval for Generic Pristiq(R)
www.bloomberg.com - April 21 at 9:51 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Provides Timing of First Quarter 2020 ResultsIntellipharmaceutics International Inc.: Intellipharmaceutics Provides Timing of First Quarter 2020 Results
www.finanznachrichten.de - April 11 at 8:05 AM
Intellipharmaceutics: Fiscal 4Q Earnings SnapshotIntellipharmaceutics: Fiscal 4Q Earnings Snapshot
finance.yahoo.com - February 29 at 8:18 PM
Intellipharmaceutics Announces Fiscal Year 2019 ResultsIntellipharmaceutics Announces Fiscal Year 2019 Results
finance.yahoo.com - February 28 at 5:25 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Resignation of Chief Financial OfficerIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Resignation of Chief Financial Officer
www.finanznachrichten.de - February 5 at 7:05 PM
Intellipharmaceutics Announces Resignation of Chief Financial OfficerIntellipharmaceutics Announces Resignation of Chief Financial Officer
finance.yahoo.com - February 5 at 7:05 PM
Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe PainIntellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
finance.yahoo.com - January 16 at 12:50 PM
FDA Ad Com thumbs down on Intellipharmaceutics oxycodone ERFDA Ad Com thumbs down on Intellipharmaceutics' oxycodone ER
seekingalpha.com - January 16 at 12:02 AM
Intellipharmaceutics down 13% ahead of Ad Com meeting on oxycodone ERIntellipharmaceutics down 13% ahead of Ad Com meeting on oxycodone ER
seekingalpha.com - January 14 at 5:02 PM
Intellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe PainIntellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
finance.yahoo.com - December 5 at 1:34 PM
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ERIntellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER
finance.yahoo.com - November 25 at 8:07 PM
Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina OdidiIntellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina Odidi
finance.yahoo.com - November 18 at 5:55 PM
Intellipharmaceutics Update on its Oxycodone ER New Drug ApplicationIntellipharmaceutics Update on its Oxycodone ER New Drug Application
finance.yahoo.com - October 24 at 6:13 PM
Intellipharmaceutics Announces Third Quarter 2019 ResultsIntellipharmaceutics Announces Third Quarter 2019 Results
finance.yahoo.com - October 11 at 5:42 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces an Update in the Purdue LitigationIntellipharmaceutics International Inc.: Intellipharmaceutics Announces an Update in the Purdue Litigation
www.finanznachrichten.de - October 6 at 1:24 PM
Intellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.Intellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.
finance.yahoo.com - September 24 at 4:49 PM
Intellipharmaceutics International Inc. Announces Update on its Oxycodone ER New Drug ApplicationIntellipharmaceutics International Inc. Announces Update on its Oxycodone ER New Drug Application
finance.yahoo.com - July 24 at 5:38 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Second Quarter 2019 ResultsIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Second Quarter 2019 Results
www.finanznachrichten.de - July 11 at 10:04 AM
Intellipharmaceutics International Inc. Announces $10,000,000 Equity Financing CommitmentIntellipharmaceutics International Inc. Announces $10,000,000 Equity Financing Commitment
finance.yahoo.com - July 9 at 11:02 AM
Intellipharmaceutics International Inc.: Intellipharmaceutics to present at the 9th Annual LD Micro InvitationalIntellipharmaceutics International Inc.: Intellipharmaceutics to present at the 9th Annual LD Micro Invitational
www.finanznachrichten.de - May 29 at 10:48 AM
U.S. FDA Acknowledges Receipt of Intellipharmaceutics Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for ReviewU.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review
finance.yahoo.com - March 29 at 12:18 PM
Intellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets SystemIntellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System
finance.yahoo.com - March 20 at 11:20 AM
Four Marijuana Stocks Green and Ready for the PickingFour Marijuana Stocks Green and Ready for the Picking
finance.yahoo.com - March 4 at 4:12 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ERIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
www.finanznachrichten.de - March 4 at 8:11 AM
Intellipharmaceutics Receives Extension from Nasdaq Hearings PanelIntellipharmaceutics Receives Extension from Nasdaq Hearings Panel
finance.yahoo.com - January 29 at 11:19 AM
Intellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based ProductsIntellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based Products
finance.yahoo.com - January 7 at 10:12 AM
This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.